NATIONAL WILMS' TUMOR STUDY - 4
国家威尔姆斯肿瘤研究 - 4
基本信息
- 批准号:3558425
- 负责人:
- 金额:$ 51.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-09-01 至 1990-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Modern treatment methods have led to major improvements in the survival
rate of children with Wilms' tumor. Combined therapy using surgery,
radiation therapy and chemotherapy now cures 90% of patients. Those with
tumors of unfavorable histology and those with metastases, either
synchronous or metachronous, are at higher risk. Their survival is in the
50-65% range, and better treatments clearly are needed. At the same time,
all therapies have their associated risks and complications, and some are
costly and inconvenient. Refinements of therapy for children with a good
outlook are therefore needed to increase efficiency, and reduce risks and
costs. NWTS-4 is designed to achieve these objectives through better
understanding of the renal tumors of childhood, their epidemiology and the
late effects of successful therapy, while conducting clinical trials of
novel therapies. These latter ask the following questions: (1) Can single
daily doses of effective chemotherapeutic agents given more frequently over
a shorter interval improve the outlook while decreasing costs and
inconvenience? (2) Can such regimens incorporating new drugs improve the
retrieval rate for patients with recurrent disease, and in so doing
identify new agents for primary care? The NWTS thus is undertaking new
tasks: the identification of new, effective chemotherapies; and the
reduction of the socio-economic burdens of therapy while striving for more
cures.
现代治疗方法大大提高了生存率
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GIULIO J D'ANGIO其他文献
GIULIO J D'ANGIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GIULIO J D'ANGIO', 18)}}的其他基金
CHILDREN'S CANCER RESEARCH: THE BIOLOGY OF NEUROBLASTOM
儿童癌症研究:神经母细胞生物学
- 批准号:
3092646 - 财政年份:1976
- 资助金额:
$ 51.64万 - 项目类别:
CHILDREN'S CANCER RESEARCH: THE BIOLOGY OF NEUROBLASTOM
儿童癌症研究:神经母细胞生物学
- 批准号:
3092647 - 财政年份:1976
- 资助金额:
$ 51.64万 - 项目类别:
相似海外基金
Novel effective combination chemotherapy using epigenetic modifiers for targeting solid tumors
使用表观遗传修饰剂靶向实体瘤的新型有效联合化疗
- 批准号:
21K06699 - 财政年份:2021
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of combination chemotherapy using NF-kappaB as molecular target for oral squamous cell carcinoma
以NF-κB为分子靶标的口腔鳞状细胞癌联合化疗的开发
- 批准号:
17K17258 - 财政年份:2017
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Improving combination chemotherapy of tuberculosis: a computational approach
改善结核病联合化疗:一种计算方法
- 批准号:
9977085 - 财政年份:2016
- 资助金额:
$ 51.64万 - 项目类别:
The establishment of individualized medicine based on the pharmacological biomarkers in bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
基于药理学生物标志物的膀胱癌患者接受含吉西他滨联合化疗的个体化治疗的建立。
- 批准号:
16K11027 - 财政年份:2016
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving combination chemotherapy of tuberculosis: a computational approach
改善结核病联合化疗:一种计算方法
- 批准号:
9294943 - 财政年份:2016
- 资助金额:
$ 51.64万 - 项目类别:
Improving combination chemotherapy of tuberculosis: a computational approach
改善结核病联合化疗:一种计算方法
- 批准号:
9157047 - 财政年份:2016
- 资助金额:
$ 51.64万 - 项目类别:
Understanding the mechanisms of drug-drug synergy in combination chemotherapy
了解联合化疗中药物协同作用的机制
- 批准号:
nhmrc : GNT1072965 - 财政年份:2015
- 资助金额:
$ 51.64万 - 项目类别:
Early Career Fellowships
Development of combination chemotherapy using NF-kappaB as molecular target for oral cancer
以 NF-κB 作为口腔癌分子靶点的联合化疗的开发
- 批准号:
26861724 - 财政年份:2014
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Mechanisms of dUTPase downregulation by oxaliplatin and its applications to combination chemotherapy
奥沙利铂下调dUTPase的机制及其在联合化疗中的应用
- 批准号:
24701028 - 财政年份:2012
- 资助金额:
$ 51.64万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Targeted Nanoparticles for Tempospatially Controlled Combination Chemotherapy
用于时空控制联合化疗的靶向纳米颗粒
- 批准号:
7983673 - 财政年份:2010
- 资助金额:
$ 51.64万 - 项目类别: